Research Guide
Growth hormone secretagogues are one of the most established categories in peptide research, but the terminology gets confusing fast, GHRH analogs, ghrelin receptor agonists, and older-generation compounds are often discussed as if interchangeable. This guide breaks down what actually distinguishes them.
Quick summary
- A secretagogue is any compound that stimulates the release of another substance — in this case, growth hormone.
- The two main receptor pathways are GHRH receptor agonists (like CJC-1295) and ghrelin receptor agonists (like Ipamorelin).
- Newer-generation ghrelin receptor agonists were developed for greater selectivity than older compounds.
- Combining a GHRH analog with a ghrelin receptor agonist is a common research approach for amplified effect.
What a secretagogue actually is
A secretagogue is a substance that triggers the secretion of another substance from a gland or cell. In this category, that means compounds studied for their ability to stimulate the pituitary gland to release growth hormone, rather than compounds that are growth hormone itself. This distinction matters because secretagogues work with the body’s natural release pattern, rather than introducing growth hormone directly.
GHRH receptor agonists
Compounds like CJC-1295 are synthetic analogs of growth hormone-releasing hormone (GHRH), the body’s natural signal for the pituitary gland to release growth hormone. Research in this category generally focuses on extending or amplifying that natural release pulse rather than replacing it.
Ghrelin receptor agonists
Compounds like Ipamorelin act on a separate pathway, the ghrelin receptor. Older-generation compounds in this category, such as GHRP-6, were associated with more pronounced side effects on cortisol and prolactin. Newer compounds like Ipamorelin were developed specifically for greater receptor selectivity, which is why they are frequently referenced as a more targeted research option within this subclass.
Why the two are often combined
Because GHRH receptor agonists and ghrelin receptor agonists act on separate, non-competing pathways, researchers frequently study them in combination. Our CJC-1295 + Ipamorelin breakdown covers this specific pairing in detail.
Read our full CJC-1295 + Ipamorelin breakdown →
Frequently asked questions
Is a secretagogue the same as growth hormone itself?
No. A secretagogue stimulates the body’s own release of growth hormone, rather than introducing growth hormone directly, which is the key distinction from recombinant HGH.
Why are older secretagogues like GHRP-6 less commonly referenced now?
Newer-generation ghrelin receptor agonists were developed for improved receptor selectivity, which is part of why compounds like Ipamorelin are more frequently discussed in current research than older-generation options.
Look up a Certificate of Analysis →
For laboratory and research use only. Not for human consumption. This article is for informational purposes; it is not medical advice.
